Today's focus

[Bohui shares: will arrange to pay 0.48 billion yuan in taxes as soon as possible in the near future]

Bohui Co., Ltd. announced that compared with the current tax policy, the company declared consumption tax of 0.428 billion yuan and additional tax of 51.3784 million yuan on August 9, 2024, for a total of 0.48 billion yuan, and will arrange payment as soon as possible in the near future. A change announcement was issued on the same day. Currently, the company is actively preparing for the resumption of work and production. As of the disclosure date of this announcement, the company has not resumed production.

Investments & Contracts

[People's Health: Proposed to sign a strategic cooperation agreement in the field of probiotics]

Minsheng Health announced that the company plans to sign strategic cooperation agreement with Pan Yulin and Zhongke Jiayi Investment Holdings Co., Ltd. to reach preliminary intentions for cooperation in the field of probiotics. The company plans to exchange 45% of the shares of Zhejiang Minsheng Health Technology Co., Ltd., a wholly-owned subsidiary, to acquire 100% of the shares in the target company and increase the capital of Health Technology before exchanging shares.

[Huifeng Co., Ltd.: Subsidiary signs cooperation agreement for green mine hydrogen energy mining area demonstration project]

Huifeng Co., Ltd. announced that its wholly-owned subsidiary Huifeng Petrochemical and Ma Steel Mining recently signed the “Green Mine Hydrogen Mining Demonstration Project Cooperation Agreement”, and the two sides will cooperate to build a “green mine hydrogen energy mine”. The overall goal of the project is to reduce carbon dioxide emissions by 0.036 million tons per year through the implementation of a green energy zero-carbon shipping emission project. After completion, the carbon reduction can be achieved by about 15%.

Changes in equity

[Daqian Ecology: Termination of changes in company control]

Daqian Ecology announced earlier that Daqian Investment, the controlling shareholder of the company, plans to transfer its 23.192 million shares of Daqian Ecology (accounting for 17.09% of the total number of shares issued by Daqian Ecology) to Tianshengyihe. This transaction will lead to a change in control of the company. The parties to the transaction held many discussions on specific issues involved in continuing to advance the transfer of control matters, but in the end, they were unable to agree on specific terms such as the delivery time, delivery conditions, and agreement on some rights and obligations of this transaction. Following friendly negotiations, the parties agreed to terminate this transfer of control. On August 11, 2024, the parties to the transaction signed the “Termination Agreement”. The actual controllers of the company are still Luan Jianhong and Fan Hedi.

Increase/decrease holdings & repurchases

[Jitai Co., Ltd.: The actual controller of the company and some executives plan to increase their holdings of the company by 10 million yuan to 15 million yuan]

Jitai Co., Ltd. announced that Zou Zhenfu, the actual controller and chairman of the company, Zou Zhenfan, director and general manager, Wu Jiayi, deputy general manager and secretary of the board of directors, Hu Yafei, deputy general manager, and Yang Qiming, plan to increase their holdings of the company through centralized bidding transactions within 6 months from the date of disclosure. The total amount of shares to be increased is not less than 10 million yuan (inclusive) and not higher than 15 million yuan (inclusive).

Operation & Performance

[Jiudian Pharmaceutical: Withdrawal of Drug Registration Application]

Jiudian Pharmaceutical announced that due to the need to further improve the relevant test data, the company recently submitted a report to the State Drug Administration to withdraw the registration application for Jiaoqi Musk Gel Patch.

[Probiotic Co., Ltd.: Sales revenue of white feather broiler seedlings fell 14.77% year on year in July]

Yisheng Co., Ltd. announced that in July 2024, the company sold 52.9819 million broiler seedlings, with sales revenue of 0.188 billion yuan. The year-on-year changes were -11.14% and -14.77%, respectively, and 2.69% and 25.23%, respectively. The number of breeding pigs sold in July was 551, with sales revenue of 1.0942 million yuan. The year-on-year changes were 533.33% and 143.94%, respectively, and the month-on-month changes were -67.87% and -75.43%, respectively.

[Xianle Health: Net profit of 0.154 billion yuan in the first half of the year increased by 52.66% year-on-year]

Xianle Health released its semi-annual report. In the first half of the year, it achieved operating income of 1.99 billion yuan, an increase of 28.85% over the previous year, and net profit of 0.154 billion yuan, an increase of 52.66% over the previous year.

[Xiang Fenghua: Net profit of 38.2408 million yuan in the first half of the year decreased by 44.92% year on year]

Xiang Fenghua released its semi-annual report. The first half of the year achieved operating income of 0.707 billion yuan, a year-on-year decrease of 28.75%, and net profit of 38.2408 million yuan, a year-on-year decrease of 44.92%.

[Huazue Testing: Net profit increased 1.97% year-on-year in the first half of 2024]

Huazue Testing released its semi-annual report. In the first half of 2024, the company achieved operating income of about 2.791 billion yuan, an increase of 9.20% over the previous year; net profit attributable to shareholders of listed companies was about 0.437 billion yuan, an increase of 1.97% over the previous year.

[Sinopharm Hyundai: The holding subsidiary's injectable cefazoxime sodium passed the generic drug consistency evaluation]

Sinopharm Hyundai announced that its holding subsidiary Sinopharm Zhijun received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration to approve the approval of injectable cefazoxime sodium to pass the consistent evaluation of the quality and efficacy of generic drugs. Cefazoxime sodium for injection is suitable for lower respiratory infections, urinary tract infections, abdominal infections, pelvic infections, etc. caused by sensitive bacteria.

[Hengrui Pharmaceutical: Notice of approval for injectable paclitaxel (albumin binding type) for drug supplementation]

Hengrui Pharmaceutical announced that it received approval from the State Drug Administration to issue a “Drug Supplement Application Approval Notice” for injectable paclitaxel (albumin binding type). The drug added an indication “suitable for combination with gemcitabine as first-line treatment for metastatic pancreatic cancer” on the basis of the approved indications.

[Maiwei Biotech: 9MW2821 is used for urothelial cancer indications and included as a breakthrough treatment variety]

Maiwei Biotech announced that recently, the innovative drug 9MW2821 was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration to treat locally advanced or metastatic urothelial cancer that has failed previous platinum chemotherapy and PD- (L) 1 inhibitor treatment, and has completed publicity.

[Netda Software: Net profit of 6.0059 million yuan in the first half of 2024 reverses losses year on year]

Netda Software released its 2024 semi-annual report. The company achieved operating income of 0.178 billion yuan in the first half of the year, an increase of 22.13% over the previous year; net profit attributable to shareholders of listed companies was 6.0059 million yuan, reversing the year-on-year loss.

Contract & Project Award

[Dashi Intelligence: Guangna Building Project Signed]

Dashi Intelligence announced that the company and Inner Mongolia Guangna Coal Industry (Group) Co., Ltd. agreed on matters related to the Guangna Building Intelligent Project and formally signed a project contract with a contract amount of 10.5 million yuan, accounting for 0.27% of the company's audited revenue in 2023.

Stock price changes

[2 Lianshen Property A: There are no significant matters that should be disclosed but not disclosed]

Shenzhen Property A issued a change announcement. After verification, there was no information disclosed by the company in the early stages that needed to be corrected or added; the company found no recent public media reports of major undisclosed information that may or have had a significant impact on the company's stock trading price; and there will be no major changes in the company's business situation or internal and external business environment recently. Up to now, the company, controlling shareholders, and actual controllers have had no major events or important matters in the planning stage that should be disclosed but not disclosed that may have a significant impact on stock transaction prices or affect investors' reasonable expectations.

other

[ST Elken: The company's shares will be delisted on August 12, 2024]

ST Elken announced that the company's stock listing has been terminated by the Shenzhen Stock Exchange and will be delisted on August 12, 2024.

[ST Fortis: The company's shares will be delisted on August 12]

ST Fortis announced that the Shenzhen Stock Exchange has decided to terminate the listing of the company's shares, and the company's shares will be delisted on August 12, 2024.

[Bank of China Cashmere: Delisted on August 12, 2024]

Bank of China Cashmere announced that the listing of the company's shares has been decided by the Shenzhen Stock Exchange and will be delisted on August 12, 2024.